 Pfenex Inc. NYSE American: PFNX announced today that the U.S. Food and Drug Administration FDA, informed Alvogen Malta Operations Ltd., the Companys commercialization partner for PF708, via a General Advice letter that additional comparative use human factors CUHF data, specifically from Forteo 